Latest / Behind the Bastards / Part Two: The Vioxx Scandal: How Big Pharma Killed More Americans Than Vietnam
Transcript
- 0:01Speaker 1: All media.
- 0:05Speaker 2: Oh we are back.
- 0:09Speaker 3: This is Behind the Bastards, a podcast with doctor tave
- 0:12Speaker 3: Hoda and Robert Evans where Sophie is out of the
- 0:16Speaker 3: house right now, so you know, we're.
- 0:18Speaker 4: Just just the boys.
- 0:21Speaker 2: The boys. No girls allowed listeners.
- 0:25Speaker 3: That's like half our listeners. Please keep listening, ladies.
- 0:28Speaker 4: Sorry, so sorry, We're we're trying to be better. I apologize.
- 0:32Speaker 4: We didn't mean that.
- 0:33Speaker 3: We didn't mean that, just like MRK didn't mean to
- 0:36Speaker 3: kill all those people that they're about to kill thanks
- 0:40Speaker 3: part to utilizing Dorothy Hamil's star appeal. Poor Dorothy, she
- 0:44Speaker 3: really did not. Again, it's one of those things where
- 0:48Speaker 3: it's like, we just shouldn't have pharmaceutical ads like the
- 0:52Speaker 3: way that we have them, because you can't. Dorothy Hamil's
- 0:57Speaker 3: was a great figure skater. Nothing in her life preparedared
- 1:00Speaker 3: her to adequately vet whether or not yacks was a
- 1:02Speaker 3: safe medication to advertise, no can't, we can't put that
- 1:06Speaker 3: on Dorothy Hamil.
- 1:07Speaker 4: No part of her training of her many hours prepared
- 1:11Speaker 4: her to look critically at the data that was available
- 1:16Speaker 4: to her. What was available to her, she wasn't even
- 1:18Speaker 4: available to her.
- 1:19Speaker 3: She wasn't getting up at four in the morning every day.
- 1:22Speaker 3: Is it like adolescent girl to have like the Cox two?
- 1:25Speaker 3: And Zime explained to her, like.
- 1:28Speaker 5: No, no, that was like me, yeah, not her. Yeah,
- 1:31Speaker 5: we had different paths different You're a terrible figure skater,
- 1:34Speaker 5: not that bad. Okay, I have never seen you figure
- 1:37Speaker 5: I've never seen you figure skate can.
- 1:40Speaker 4: Cow maybe sure? Is that like a skateboarding move?
- 1:44Speaker 2: Yeah? Probably Yeah.
- 1:47Speaker 3: This has been skate talk with Robert and Cava to
- 1:50Speaker 3: people who probably don't skate. So when we left our
- 1:57Speaker 3: heroes at Bios, they just latched upon the brilliant of
- 2:00Speaker 3: having Dorothy Hamill sell box. If you've been wondering how
- 2:04Speaker 3: tens of millions of your fellow countrymen could be convinced
- 2:06Speaker 3: to vote for a guy like Trump, just remember that
- 2:09Speaker 3: an awful lot of them saw a video of a
- 2:10Speaker 3: figure skater promising she knew a solution to their chronic
- 2:13Speaker 3: pain issues and desperate for relief. Millions of people followed
- 2:18Speaker 3: her to their demise. Like that really does explain a lot. Now,
- 2:25Speaker 3: in fairness, very few people are doctors. It is unreasonable
- 2:28Speaker 3: to expect people who are hurting and in some cases
- 2:30Speaker 3: literally being driven mad by pain to personally overcome the
- 2:34Speaker 3: weight of a multimillion dollar ad campaign and all of
- 2:36Speaker 3: the science washing that a big pharmaceutical company can do.
- 2:39Speaker 3: In fact, during the early years of iax's success, it
- 2:42Speaker 3: would have seemed as if Cox two inhibitors were medical
- 2:45Speaker 3: marvels backed by the best science, and it would have
- 2:48Speaker 3: seemed that if you were someone who did what should
- 2:51Speaker 3: be like the responsible amount of reading on this subject,
- 2:55Speaker 3: not like the amount of reading that we could expect
- 2:57Speaker 3: from like a research scientist, because research scientist who we're responsible,
- 3:01Speaker 3: knew the dangers. But if you were, say, like a
- 3:04Speaker 3: normal educated person who's like, oh, well, I'm going to
- 3:07Speaker 3: read a paper of record and they're reporting on these
- 3:10Speaker 3: new drugs written by a medical doctor interviewing other medical doctors.
- 3:13Speaker 3: That's really all you, as a layman, should be.
- 3:16Speaker 6: Expected to do to try to figure out, you know,
- 3:19Speaker 6: how safe a medication is.
- 3:22Speaker 3: And if you were doing that with viox, you would
- 3:25Speaker 3: have walked away misinformed. And this brings us to one
- 3:28Speaker 3: of the chief medical merchants of viox disinfo, a Harvard
- 3:32Speaker 3: Medical School professor named doctor Jerome Grutman. He had embarked
- 3:37Speaker 3: on a career as what you might call a professional
- 3:39Speaker 3: semi celebrity doctor authoring articles for The New Yorker about
- 3:42Speaker 3: health and the pharmaceutical industry, which he does today. Doctor
- 3:46Speaker 3: Grutman is not someone who you would call the crank.
- 3:48Speaker 3: He served in the advisory board of the National Heart, Lung,
- 3:52Speaker 3: and Blood Association. He was the Dina and Raphael Recanati
- 3:56Speaker 3: Chair of Medicine at Harvard Medical School. He'd worked at
- 3:59Speaker 3: a high level for the s and was a listed
- 4:01Speaker 3: author on some one hundred and fifty papers. One of
- 4:03Speaker 3: his books had been adapted into a TV show, Gideon's Crossing,
- 4:07Speaker 3: which I didn't expect to run into a Gideon's Crossing
- 4:10Speaker 3: references amiteral on this episode. It wasn't great, as tom
- 4:16Speaker 3: NeSSI writes in the book Poison Pills, even among top
- 4:19Speaker 3: level physicians who are generally known as opinion or thought leaders,
- 4:22Speaker 3: Groupman stands out it was no small matter. Therefore, when
- 4:25Speaker 3: he wrote a linky article for The New Yorker in
- 4:27Speaker 3: June of nineteen ninety eight entitled super aspirin new arthritis
- 4:31Speaker 3: drug Celebra. Celebra was the name for the drug lender
- 4:34Speaker 3: and as celebres, and very close in composition to viox.
- 4:37Speaker 3: The article had been carefully authenticated by the famous fact
- 4:40Speaker 3: checking department of The New Yorker, which is an almost
- 4:42Speaker 3: perfect record of verifying every piece of information the magazine publishes.
- 4:46Speaker 3: Like Hamill, Groupman began his discussion of super aspirin with
- 4:49Speaker 3: a personal story. He himself had suffered debilitating pain brought
- 4:52Speaker 3: on by oarthritis developed while training for the Boston Marathon.
- 4:56Speaker 3: Despite years of searching for relief, he had found no
- 4:58Speaker 3: satisfactory remedy. How or remarkable new class of drugs was
- 5:01Speaker 3: offering hope to people like him and millions of others,
- 5:05Speaker 3: and Groupman provided the anecdotal story of a firefighter from
- 5:08Speaker 3: Nebraska whose arthritis had been alleviated miraculously thanks to super aspirin.
- 5:13Speaker 3: A responsible scientist would note that the anecdotal evidence was
- 5:16Speaker 3: more fit for a pharmaceutical commercial than an article in
- 5:19Speaker 3: The New Yorker by a doctor. But doctor Grupman did
- 5:22Speaker 3: speak with other medical experts, like Harvard's doctor Lee Simon,
- 5:25Speaker 3: who had a seat on the FDA's Arthritis Advisory Committee
- 5:28Speaker 3: and had been part of an FDA panel to evaluate
- 5:31Speaker 3: how to approve super aspirins. This probably shouldn't have been
- 5:35Speaker 3: allowed to happen because while he was sitting on that
- 5:37Speaker 3: FDA panel deciding how to approve these medications. Doctor Simon
- 5:42Speaker 3: was also a paid employee of Seerle conducting clinical trials
- 5:46Speaker 3: for celebres. He did not disclose this conflict of interest,
- 5:50Speaker 3: and doctor Grutman's article did not make any note of
- 5:53Speaker 3: this fact that might have compromised a source's objectivity.
- 5:56Speaker 4: That's actually pretty shocking, I have to say. I mean,
- 5:59Speaker 4: because I mean, I know it's not a medical journal
- 6:03Speaker 4: that he's writing in, but that is like the New
- 6:05Speaker 4: Yorker though, Like I mean, yeah, you would think he
- 6:07Speaker 4: would he would know, he should know better. Like that
- 6:10Speaker 4: is like if you write anything. I wrote a piece
- 6:14Speaker 4: in the BMJ recently, and I had to disclose everything,
- 6:17Speaker 4: including who I was voting for, yeah, you know, in
- 6:19Speaker 4: the election. So it's like in who I donated money
- 6:22Speaker 4: to in the election. So that's pretty shocking to me that,
- 6:24Speaker 4: like they did not require.
- 6:26Speaker 3: That, they didn't require that. It's unclear to me if
- 6:28Speaker 3: Grutman knew that doctor Simon was a plaid employee of Cerle.
- 6:31Speaker 3: But I don't think Grutman is doing as much of
- 6:34Speaker 3: his due diligence as he ought to. Saw what Simon
- 6:36Speaker 3: is doing is obviously the more shady of the thing, but.
- 6:38Speaker 2: It's one of those this is what I say.
- 6:40Speaker 3: What I'm like, you really I just made that comment
- 6:43Speaker 3: about like people being led by a figure skater, but like, yeah, again,
- 6:47Speaker 3: if you're if you're doing your research, you could still
- 6:50Speaker 3: get misled about this stuff, right, absolutely.
- 6:53Speaker 4: I mean by a Harvard doctor. I mean, if COVID
- 6:56Speaker 4: has done nothing else. It has also raised some doubts about,
- 6:59Speaker 4: you know, the reputation of places here in the Bay Area,
- 7:03Speaker 4: like UCS, SAT and Stanford where a lot of you know,
- 7:06Speaker 4: anti vaccine cranks seem to be coming out of. So like,
- 7:10Speaker 4: it's not totally shocking to me that it's Harvard, you know,
- 7:13Speaker 4: but I could absolutely see the danger in someone with
- 7:17Speaker 4: a name that big, the H bomb you dropping there,
- 7:21Speaker 4: leading people to believe this this in New York must
- 7:24Speaker 4: be right, the intellectual elites, you know, leading them all
- 7:27Speaker 4: to believe the safety of it.
- 7:29Speaker 2: Yeah.
- 7:29Speaker 3: And and Simon's quotes in The New Yorker are It's
- 7:32Speaker 3: one of those things. He's really relying a lot on
- 7:35Speaker 3: the fact that he's this fancy Harvard doctor, because the
- 7:37Speaker 3: shit he is actually saying in this article is shit
- 7:40Speaker 3: no doctor should ever say. He described celebrates as incredible
- 7:44Speaker 3: and told doctor Grutman that unique among all other medications
- 7:49Speaker 3: ever created, it had no side effects whatsoever. Specific they stated,
- 7:54Speaker 3: there are no side effects, which most don't exist. You
- 7:58Speaker 3: might not experience side eft, but someone will. There's no
- 8:02Speaker 3: drug that has zero side effects of any kind.
- 8:05Speaker 4: It's not a drug. If it's if I am doing
- 8:08Speaker 4: the safest procedure in the world, I am never ever
- 8:11Speaker 4: gonna say this is no risk because that's like jinxing it.
- 8:14Speaker 4: Why would you do that. You never do that. It's
- 8:17Speaker 4: just stupid. It's untrue.
- 8:18Speaker 2: That is zero shocking.
- 8:20Speaker 4: I mean, this is maybe that's a big old red flag. Wow. Yeah,
- 8:24Speaker 4: And this is.
- 8:25Speaker 3: This is I think where it gets into like the
- 8:27Speaker 3: value of actually having a higher level of like kind
- 8:30Speaker 3: of medical like medical even training. It may not be
- 8:33Speaker 3: totally the right world, but like word, but like in school,
- 8:35Speaker 3: so that because that's the sort of thing it is
- 8:38Speaker 3: easy to like train people to have people in general,
- 8:42Speaker 3: Layman be aware of, like, oh, if I see that,
- 8:44Speaker 3: if I see somebody claiming there are zero side effects
- 8:46Speaker 3: for anyone of this medication, that's something you shouldn't That's sketchy.
- 8:50Speaker 3: You know, absolutely so, Asnessi notes, this should have been
- 8:54Speaker 3: a massive and immediate red flag, just as we noted.
- 8:56Speaker 3: But yeah, Doctor Grutman's article cited other medical experts making
- 9:01Speaker 3: similarly dubious claims. He quoted another Harvard professor, doctor Clifford Saper,
- 9:06Speaker 3: as saying super aspirin might hold the key to treating Alzheimer's. Now,
- 9:09Speaker 3: this is a case where there was not evidence that
- 9:11Speaker 3: it had efficacy treating Alzheimer's. Doctor Saper had a theory
- 9:15Speaker 3: that inflammation in the brain caused by injured neurons led
- 9:18Speaker 3: to swelling the damaged brains, and that as a result,
- 9:21Speaker 3: viox might help. Right, And that's a perfectly valid thing
- 9:24Speaker 3: to want to test.
- 9:26Speaker 4: Right, yea.
- 9:26Speaker 3: But you shouldn't go out an article be like this
- 9:28Speaker 3: might here Alzheimer's based on that, because that's just a theory, right.
- 9:32Speaker 4: And you know, and it's read, it's read by people
- 9:35Speaker 4: understandably who are going to then relate it to somebody
- 9:38Speaker 4: else as this is what it does. This is like
- 9:41Speaker 4: we think it does this, and like there's so many steps.
- 9:45Speaker 4: There's so many steps. There's years of steps between point
- 9:49Speaker 4: A and point B, and that.
- 9:50Speaker 3: Yep, and yeah so quote. Doctor Saper said that celebrc's
- 9:54Speaker 3: probest to break open the vicious cycle of inflammation in Alzheimer's.
- 9:58Speaker 3: Quite an astonishing statement of itself, and even more so
- 10:01Speaker 3: since he did not cite results of a single human study.
- 10:04Speaker 3: Yet the claim is part of an age old school
- 10:05Speaker 3: of medical thinking that holds that logic in what makes
- 10:08Speaker 3: sense or rational therapy should dictate the practice of medicine.
- 10:11Speaker 3: But rational therapy needs to be buttressed by randomized, controlled
- 10:14Speaker 3: human trials to determine what is and what is not
- 10:16Speaker 3: effective treatment. That's from the book Poison Pills Now. Theorizing
- 10:21Speaker 3: like Sabrid did is of course part of the medical process,
- 10:23Speaker 3: but maybe not one that should be presented to the
- 10:25Speaker 3: public in a widely read article where like people who've
- 10:28Speaker 3: got loved ones suffering from Alzheimer's are going to be like,
- 10:30Speaker 3: oh my god, a miracle drug might be coming through. No,
- 10:33Speaker 3: even if it works, it's fucking fifteen years out or whatever,
- 10:36Speaker 3: like from you know. Grutman's article also wildly exaggerated the
- 10:40Speaker 3: harms of existing insets like Motrin and advil, failing to
- 10:43Speaker 3: discuss newer versions that had been approved and came with
- 10:46Speaker 3: fewer of the side effects that so called super aspirin
- 10:48Speaker 3: was meant to avoid. In his article, Grupman cited the
- 10:51Speaker 3: work of doctor James Frees, a professor at Stanford at length.
- 10:54Speaker 3: Freese himself claims Grutmann distorted his research in order to
- 10:58Speaker 3: make claims that Freese was not making about Cox two inhibitors. Now,
- 11:03Speaker 3: doctor Grutman was not being bribed by merk nor did
- 11:06Speaker 3: he violate the law or medical ethics in any way
- 11:08Speaker 3: that I'm aware of other than writing a bad article.
- 11:11Speaker 3: He fucked up, and part of why he fucked up was,
- 11:14Speaker 3: in my opinion, he was looking to merge developing medical
- 11:17Speaker 3: science with magazine Pop Science in a way that's not
- 11:20Speaker 3: wildly different from what Malcolm Gladwell is going to be
- 11:22Speaker 3: doing a few years later.
- 11:23Speaker 4: Right.
- 11:23Speaker 3: I think that's irresponsible, but not malicious or outright criminal. Right,
- 11:27Speaker 3: And we are talking about some people who did outrite
- 11:29Speaker 3: criminal acts in this. I want to make it clear,
- 11:30Speaker 3: I am not accusing doctor Grutman of doing anything criminal
- 11:35Speaker 3: the same but not But.
- 11:37Speaker 4: It's a slippery slope. It is, I mean it.
- 11:38Speaker 3: Is, and see why it leads to people doing it.
- 11:41Speaker 4: You know, And I've said this to you before too.
- 11:43Speaker 4: It's like I think in the past, you know, when
- 11:45Speaker 4: I was earlier in my medical training of my career,
- 11:48Speaker 4: I didn't care that much about things like that. I
- 11:50Speaker 4: would probably read it and be like, what is he saying?
- 11:52Speaker 4: What does he mean? Forget it and let it go,
- 11:55Speaker 4: not worry about that much. But this is how it starts.
- 11:58Speaker 4: This is how it starts. It raises enough doubt, it
- 12:00Speaker 4: raises enough like it makes it vague enough, it makes
- 12:04Speaker 4: it cloudy enough that it's hard for people to know
- 12:07Speaker 4: what is real and what isn't real. And this is
- 12:09Speaker 4: where medical information, like the roots of it begin. It
- 12:12Speaker 4: begins in good places sometimes like a Harvard doctor.
- 12:16Speaker 3: Yeah, it's it's it's the same thing where we have
- 12:20Speaker 3: this problem in journalism.
- 12:21Speaker 4: Right.
- 12:22Speaker 3: There's a great movie called Shattered Glass starring Haymen Christensen
- 12:25Speaker 3: about about a journalist for the New Republic who was
- 12:30Speaker 3: like their star reporter, super young, and it turned out
- 12:32Speaker 3: all of his stories he was just making them up,
- 12:34Speaker 3: like complete bullshit, like literally just inventing people and things
- 12:38Speaker 3: in order to write entertaining stories. The New York Times
- 12:42Speaker 3: a little bit later had another reporter get blown up.
- 12:44Speaker 3: A star reporter for the same thing, just completely lying
- 12:46Speaker 3: about shit, tricking fact checkers, and it's one of those
- 12:49Speaker 3: things doesn't have to happen all that often for people
- 12:53Speaker 3: to be like, well, then these outlets are no better
- 12:56Speaker 3: than whatever like weird fucking conspiracy, rag info wars or
- 13:00Speaker 3: whatever that I like. And you know what, that's kind
- 13:02Speaker 3: of on the journalists for fucking up in that way, right,
- 13:05Speaker 3: that's on the newsroom, that's on the editors. That's on
- 13:07Speaker 3: to people wanting these big stories that are exciting and
- 13:12Speaker 3: that get eyeballs on. Right here, you kind of have
- 13:14Speaker 3: the merger of the two. Right, the New Yorker wants
- 13:16Speaker 3: an article that gets a lot of people to read it,
- 13:18Speaker 3: because fuck, this is a miracle medicine that might help
- 13:21Speaker 3: me and my loved ones with things that are really
- 13:23Speaker 3: like causing us problems. And as the doctor, you want
- 13:27Speaker 3: to be the first. You want to be the doctor
- 13:28Speaker 3: who kind of establishes himself as like, I'm kind of
- 13:31Speaker 3: on the ground floor of this breaking for people.
- 13:33Speaker 4: I'm here right treat people. And there's going to be
- 13:35Speaker 4: people who are going to be upset if Celebrates goes
- 13:38Speaker 4: away or if these medications go away, because there are
- 13:40Speaker 4: people out there who like, this is the one that
- 13:42Speaker 4: works for me.
- 13:43Speaker 3: Yeah, fucked so again. I just made the point that
- 13:48Speaker 3: Grupman was not breaking the law. The same cannot be
- 13:50Speaker 3: said for the next doctor we're going to discuss, an
- 13:53Speaker 3: anesthesiologist named Scott Rubin. Starting in the year two thousand,
- 13:57Speaker 3: Rubin published what would become twenty one papers claiming to
- 14:00Speaker 3: show evidence that COX two inhibitors performed better than nonsteroidal
- 14:03Speaker 3: anti inflammatory drugs for patients who'd received orthopedic surgery. Now,
- 14:08Speaker 3: the last episode we mostly focused on Murk, and we
- 14:10Speaker 3: will later in this one as the bulk of the
- 14:12Speaker 3: blame lies with them. But our old friends at Pfiser
- 14:14Speaker 3: don't have totally clean clean hands.
- 14:16Speaker 4: Here.
- 14:17Speaker 3: Ruben was largely pushing a line that Peiser's product celebrates
- 14:20Speaker 3: was a game changer, and that it was when it
- 14:23Speaker 3: was paired with neurontin and Lyrica, both Pheiser products together
- 14:26Speaker 3: they safely reduced post operative pain and could help eliminate
- 14:29Speaker 3: the need for dangerous addictive drugs like morphine after surgery.
- 14:33Speaker 3: Piser funded a great deal of Reuben's research from two
- 14:36Speaker 3: thousand and two to two thousand and seven, effectively picking
- 14:38Speaker 3: him up after he'd established himself as an expert in
- 14:41Speaker 3: the burgeoning field of COX two inhibitor research. The good
- 14:45Speaker 3: news is that, in the field Reuben attempted to influence
- 14:48Speaker 3: orthopedic surgery, his work had less of an influence than
- 14:51Speaker 3: he'd hoped. Most surgeons hesitated to switch to COX two
- 14:54Speaker 3: inhibitors because some very good animal studies showed they slowed
- 14:57Speaker 3: the rate at which bones heel, which is kind of
- 14:59Speaker 3: a big deal if you're in the orthopedic surgery business.
- 15:02Speaker 4: Wow, I'm just impressed that the orthopedic surgeons were reading anything. Hey, sorry,
- 15:09Speaker 4: big the orthopedic surgeons.
- 15:14Speaker 3: Speaking of orthopedic surgeons. They don't listen to podcasts, so
- 15:20Speaker 3: fuck them. Here's some ads.
- 15:28Speaker 2: And we're back.
- 15:29Speaker 3: If you're an orthopedic surgeon, hit me up. I got
- 15:33Speaker 3: too many bones. I could use a couple less. Probably, so,
- 15:37Speaker 3: Ruben's work formed an influential mass of positive seeming scientific
- 15:41Speaker 3: pr arguing in favor of drugs like Biax and celebrates
- 15:44Speaker 3: as safer super aspirins. An article in Scientific American notes.
- 15:48Speaker 3: A two thousand and seven editorial in Anesthesia and Analgesia
- 15:52Speaker 3: stated that Ruben had been at the forefront of redesigning
- 15:54Speaker 3: pain management protocols through his carefully planned and meticulously documented studies.
- 16:00Speaker 4: Was to say that him he called his own studies.
- 16:02Speaker 3: No, that's what the an editorial to how like the
- 16:05Speaker 3: editors of the paper described him. And there's only one
- 16:08Speaker 3: problem with these carefully the twenty or so carefully planned
- 16:11Speaker 3: and meticulously documented studies that he had authored over a
- 16:13Speaker 3: twelve year period, they were all complete bullshit, fraudulent in
- 16:17Speaker 3: every way. Now, we will talk more about Reuben later
- 16:20Speaker 3: because a lot of history occurs after the collapse of Yox,
- 16:22Speaker 3: But it's important to note that Justice Pfeiser underwrote ruben
- 16:25Speaker 3: shoddy research. Murk had deeply questionable science that they funded
- 16:29Speaker 3: in an equally dubious way. Back during the FDA approval process,
- 16:33Speaker 3: Merk had launched a strategy called Advantage in all caps
- 16:36Speaker 3: because it was a very tortured acronym assessment differences between
- 16:40Speaker 3: biox and neproxyen to ascertain gastronomical tolerability and effectiveness. An
- 16:45Speaker 3: analysis by the Union of Concerned Scientists describes the goal
- 16:48Speaker 3: of Advantage as using flawed methodologies toward bias towards predetermined
- 16:52Speaker 3: results to exaggerate the drug's positive effects. Quote as part
- 16:55Speaker 3: of their strategy, scientists manipulated the trial data by comparing
- 16:58Speaker 3: the drug to neproxen, a pain reliever sold under brand
- 17:01Speaker 3: name such as a leave rather than a placebo. And yeah,
- 17:04Speaker 3: we covered that a little earlier. But what's important is
- 17:07Speaker 3: that we now know that Merk had a great deal
- 17:09Speaker 3: of evidence when they were pushing this study suggesting that
- 17:13Speaker 3: like viox massively increased the risk of cardiovascular events, which
- 17:16Speaker 3: makes the case that this was not just something where
- 17:19Speaker 3: they did a bad study and put this thing next
- 17:21Speaker 3: to to proxen and it looked less risky than it
- 17:23Speaker 3: does because it was next to a proxy and they
- 17:25Speaker 3: conducted that study with new proxyen because they had data
- 17:28Speaker 3: showing that viox massively increased the risk of heart attacks,
- 17:32Speaker 3: and they were deliberately trying to hide that.
- 17:35Speaker 4: Right.
- 17:35Speaker 3: This is all stuff that came out later as a
- 17:37Speaker 3: result of the Senate investigation and numerous court cases. So yeah,
- 17:41Speaker 3: we know that Mark had a lot of evidence showing
- 17:43Speaker 3: this was dangerous and they deliberately hit it. And we
- 17:46Speaker 3: know that this was incredibly profitable for Merk. From nineteen
- 17:49Speaker 3: ninety nine to two thousand and four, Viox made them
- 17:51Speaker 3: two and a half billion dollars a year on average.
- 17:54Speaker 3: It swiftly became the best selling drug in MRK history
- 17:57Speaker 3: and one of the best selling drugs of all time,
- 18:00Speaker 3: and just as swiftly, it started to kill people. One
- 18:03Speaker 3: of the first to die was Bob Ernst. He was
- 18:05Speaker 3: a fit, fifty nine year old triathlete who started taking
- 18:08Speaker 3: biox because of recurrent arthritic pain in his hand. His wife,
- 18:12Speaker 3: Carol had urged him to try ViOS after seeing an
- 18:14Speaker 3: ad and Bob had gone on the medication. On May sixth,
- 18:17Speaker 3: two thousand and one, the two at an anniversary date
- 18:20Speaker 3: at an olive garden in Keene, Texas. Bob passed away
- 18:23Speaker 3: in his sleep later that night, dead from heart failure. Now,
- 18:27Speaker 3: Bob had been in very good shape, but the death
- 18:29Speaker 3: of a fifty nine year old man from heart failure
- 18:31Speaker 3: is simply not the kind of thing that most pathologists
- 18:33Speaker 3: are going to consider super suspicious. It was Carol herself
- 18:37Speaker 3: who got suspicious, so since started digging into Bob's one
- 18:40Speaker 3: medications is the only thing. He was prescribed biox. Even
- 18:43Speaker 3: as early as two thousand and one, there were studies
- 18:45Speaker 3: showing that Vyas was bad for heart health. Murck had
- 18:48Speaker 3: successfully buried many of them, but there was still stuff
- 18:50Speaker 3: that you could find with enough digging online. And that's
- 18:53Speaker 3: exactly what his wife did. She found a lawyer, Mark Lanier,
- 18:57Speaker 3: who made to take her case. In the book Poison
- 18:59Speaker 3: Pill does a wonderful job of chronicling the work that
- 19:02Speaker 3: they did. I'm going to have to give you a
- 19:03Speaker 3: summary here, which is that in August of two thousand
- 19:05Speaker 3: and five, a Texas state jury awarded almost twenty five
- 19:09Speaker 3: million dollars to Carol Earnst in compensatory damages and more
- 19:12Speaker 3: than two hundred million impunitive damages.
- 19:14Speaker 2: Now that latter a.
- 19:15Speaker 3: Matt verdict was lowered quite a bit due to a
- 19:17Speaker 3: Texas law, but would be fair to call this a
- 19:19Speaker 3: massive victory against Merk, and much of the case against
- 19:22Speaker 3: Merk hinged on the fact that in June of two thousand,
- 19:25Speaker 3: Merck had provided a tranch of early user data to
- 19:28Speaker 3: the FDA that revealed vyox users had four times as
- 19:31Speaker 3: many heart attacks as people on the prox and they
- 19:33Speaker 3: didn't state this though this was in the data. You
- 19:36Speaker 3: could find it if you analyze the data, but it
- 19:38Speaker 3: was not in any of the conclusions that like Merk
- 19:41Speaker 3: sent along to the FDA. And the FDA really just
- 19:44Speaker 3: didn't do the work to actually like figure this out
- 19:47Speaker 3: very quickly, and so it wasn't until fourteen months later
- 19:50Speaker 3: in April of two thousand and two that the FDA
- 19:53Speaker 3: actually forced through changes and how viox was labeled to
- 19:56Speaker 3: reflect the evidence of risk. Merk took no action on
- 19:59Speaker 3: their own to warn users about the fact that they
- 20:01Speaker 3: knew that viox was causing heart attacks. Now, in the
- 20:05Speaker 3: Leader trial that would develop from all this, CEO Raymond
- 20:08Speaker 3: Gilmartin would claim that Vyox wanted to add a warning
- 20:11Speaker 3: label the instant they were aware of the danger. This
- 20:13Speaker 3: was a lie, as Cope and Barry Wright in their
- 20:15Speaker 3: article Mirk in the Viox Debacle. Lanier, that's the lawyer
- 20:19Speaker 3: introduced in the Ernst trial internal Mirk documents, which revealed
- 20:23Speaker 3: that Merck resisted the FDA's efforts to add warnings to
- 20:26Speaker 3: Vyax's label and eventually complied in ways that the Ernst
- 20:29Speaker 3: jury found obscure. You had to dig three levels to
- 20:31Speaker 3: see it, one juror stated in March two thousand, when
- 20:34Speaker 3: Merk became aware of the Vigor studies findings of a
- 20:37Speaker 3: significant increase in cardiovascular events for those taking vax over
- 20:40Speaker 3: into Prox, and Merks scientists expressed concern. In an email
- 20:43Speaker 3: message written in March of two thousand, Doctor Edward Skolnik,
- 20:46Speaker 3: who was then Merk's head of research, stated the Vigor
- 20:49Speaker 3: clinical trial had shown that vyax increased heart risks. The
- 20:52Speaker 3: CV events were clearly there, he wrote, despite clear warnings,
- 20:56Speaker 3: Merk Deskis decided against conducting studies on the heart attack
- 20:59Speaker 3: risks because the marketing executives worried it might hurt Biox sales.
- 21:03Speaker 3: Internal mIRC analyzes in two thousand and two thousand, two,
- 21:05Speaker 3: two thousand and one, and two thousand and two showed
- 21:07Speaker 3: that Merk was worried about lost profits if warnings or
- 21:10Speaker 3: precautions were put on its label. During that period, Mirk
- 21:13Speaker 3: was in private negotiations with the FDA over changes to
- 21:16Speaker 3: its Yox label. David Anstis, who at that time was
- 21:19Speaker 3: the president of Merk's Human Health division, projected that a
- 21:22Speaker 3: strict warning would reduce sales by at least fifty percent
- 21:25Speaker 3: after the Vigor study findings in March of two thousand.
- 21:28Speaker 3: A second internal mIRC analysis performed in October two thousand
- 21:31Speaker 3: showed a significant increase in cardiovascular events for those taking vyox.
- 21:35Speaker 3: The mIRC analysis plaintiff's atorney Mark Laneer, has argued was
- 21:39Speaker 3: never presented to the FDA nor the media, and certainly
- 21:42Speaker 3: was not given to the physicians for scribing byox. So
- 21:45Speaker 3: this is entirely the marketing team and the CEO coming
- 21:48Speaker 3: in and saying like this will cut profits, So bury
- 21:52Speaker 3: it as long as you can. Every additional year we
- 21:54Speaker 3: get to sell this stuff without a warning. Is worth
- 21:57Speaker 3: it to us? Right, whatever number of deaths there are,
- 22:00Speaker 3: the money this is bringing in is so huge, Like
- 22:02Speaker 3: it's fine, right, that's literally a decision being made.
- 22:06Speaker 4: You know. It's like the what's interesting to me is
- 22:09Speaker 4: looking at these things is what could the FDA have
- 22:12Speaker 4: done better in some of these circumstances. It's hard because
- 22:15Speaker 4: some of the information is just not being given to
- 22:17Speaker 4: them in what seems like a very fraudulent manner. But
- 22:21Speaker 4: they need to have the power to do certain they
- 22:25Speaker 4: need to teeth to do certain things. When a drug
- 22:27Speaker 4: is first approved, there's still a lot of unanswered early
- 22:32Speaker 4: safety questions because for most of the studies that are
- 22:35Speaker 4: getting them approved, there's like maybe two to four thousand
- 22:39Speaker 4: at most patients in a study. Sometimes oftentimes that's not
- 22:43Speaker 4: enough to see like the safety evidence and what risks
- 22:47Speaker 4: are associated with it. So the FDA has to be
- 22:50Speaker 4: there pushing to see more data making sure that it
- 22:53Speaker 4: stay safe. Once those numbers come out, they need to
- 22:56Speaker 4: be there to do the post marketing studies. It's it's
- 23:00Speaker 4: interesting to me to see it's terrifying to me to
- 23:03Speaker 4: see going back to what's coming in the future, what's
- 23:05Speaker 4: going to happen to our fdo god and how deregulated
- 23:09Speaker 4: it's going to become, and to see what they're going
- 23:11Speaker 4: to be able accomplish. It's it's going to be I mean,
- 23:15Speaker 4: I just I mean, I hate to say it, but
- 23:17Speaker 4: I think we're going to see more drug induced injuries
- 23:22Speaker 4: than ever before because more medicines are going to be
- 23:25Speaker 4: coming out and few of them are going to have
- 23:27Speaker 4: the post marketing studies to prove it.
- 23:31Speaker 3: And that's that's what's fucking scary, right is that, like
- 23:34Speaker 3: we're talking, this is a massive failure by the FDA too.
- 23:38Speaker 3: That happened when it was funded, right, like we can
- 23:41Speaker 3: argue should have been funded more, but like that happened
- 23:43Speaker 3: in a period totally different from the one we're entering into. Now, Like,
- 23:47Speaker 3: what kind of shit is going to go come by
- 23:49Speaker 3: now that there's there's no guardrails on any of this stuff, right,
- 23:53Speaker 3: Like these fucking MBAs who are managing all of these
- 23:56Speaker 3: pharmaceutical companies have absolutely and these marketers have absolutely no
- 24:01Speaker 3: restrictions anything that they can shovel into people's faces to
- 24:04Speaker 3: make a profit.
- 24:06Speaker 4: It's funny. I'm like, you know, I get a lot
- 24:08Speaker 4: of shit online for being like a pharma shill because, like,
- 24:12Speaker 4: you know, I promote vaccines, like because they work and
- 24:16Speaker 4: they're great, and you know, I can go into that
- 24:20Speaker 4: in great detail if you like. But like, the the
- 24:24Speaker 4: funny thing is the people, those people who are so
- 24:26Speaker 4: against drug companies, so few of them are against drug
- 24:30Speaker 4: companies for the right reason, for reasons like this. You know,
- 24:33Speaker 4: when there's real reason to be mad about pharmaceutical companies,
- 24:37Speaker 4: more people are upset about like the vaccines that have
- 24:41Speaker 4: come out with good data behind them and with good
- 24:44Speaker 4: studies in the limited amount of time that they're able
- 24:46Speaker 4: to do. You know, it is it is hard. It's
- 24:50Speaker 4: hard for me to wrap my brain around that. How
- 24:53Speaker 4: I have to be the one defending pharmacuol companies and
- 24:57Speaker 4: I'm asked, skeptical of them as anybody, Yeah, because of
- 25:00Speaker 4: shit like this and then stuff we've seen.
- 25:02Speaker 3: Like this, and it's yeah, it's just fucking I mean,
- 25:07Speaker 3: what's coming is going to be sick folks in a
- 25:09Speaker 3: very literal term. But what happened in the past was
- 25:12Speaker 3: pretty sick too. So it took about four years for
- 25:15Speaker 3: the Carol Ernst legal case to wind on against Bios
- 25:18Speaker 3: right from her realizing there was probably something wrong with
- 25:21Speaker 3: her husband's medication to actually getting a victory, which is
- 25:24Speaker 3: actually pretty quick for one of these lawsuits.
- 25:26Speaker 4: Ye.
- 25:27Speaker 3: The company continued to push the mountain of disinformation during
- 25:30Speaker 3: this time about their new star medications dangers. One February
- 25:34Speaker 3: two thousand and one sales memorandum for bade sales rep
- 25:36Speaker 3: from discussions on a study that raised heart concerns when
- 25:40Speaker 3: they talk to physicians. Right, can't talk about this study
- 25:43Speaker 3: about heart attacks from our medication when you sell it
- 25:45Speaker 3: to doctors. Salespersons were also ordered to avoid discussing heart
- 25:49Speaker 3: health risks and instead hand over a cardiovascular card to
- 25:53Speaker 3: physicians which said Vyox is protecting the heart rather than
- 25:57Speaker 3: potentially harming it. To take care of all of their
- 26:01Speaker 3: questions oh good, you give me a card. Well, you
- 26:03Speaker 3: got you guys got card money. There must be nothing
- 26:06Speaker 3: wrong with this stuff could afford this kind of embossing.
- 26:10Speaker 3: My god, look at that. It's okay, guys, they gave
- 26:13Speaker 3: me a card.
- 26:14Speaker 4: Good.
- 26:16Speaker 3: The Ernst lawsuit was not the first or last against Mirk.
- 26:19Speaker 3: Most were brought by survivors of heart attacks or morole
- 26:23Speaker 3: and the family members of people who had perished. Mirk
- 26:25Speaker 3: upped their game, as this passage from Colpenberry's article makes clear,
- 26:30Speaker 3: Mirk prepared an in house training game for Vyox sales representatives,
- 26:33Speaker 3: dubbed Dodgeball. Sales trainees could only move on to the
- 26:37Speaker 3: next round of the card game if they gave Merk
- 26:39Speaker 3: approved answers to doctors questions raising Vyox safety concerns, or
- 26:43Speaker 3: dodged such questions altogether.
- 26:46Speaker 4: Wow, dodgeball.
- 26:47Speaker 2: They're literally playing.
- 26:48Speaker 3: Dodgeball with their death medicine, you know, questions about their
- 26:54Speaker 3: death medicine.
- 26:55Speaker 4: It is death medicine. It is interesting. Like they they
- 26:59Speaker 4: the way they train their reps, like they train them
- 27:03Speaker 4: to deal with different types of doctors. They're very smart.
- 27:06Speaker 4: They recognize that there's like four or five different types
- 27:09Speaker 4: of doctors and They range from like the owl, which
- 27:12Speaker 4: is like the name they'd give one when they're training sessions,
- 27:15Speaker 4: which is the guy you want to avoid, the person
- 27:18Speaker 4: you want to avoid because they're going to ask them
- 27:19Speaker 4: more detailed questions. They're going to keep drilling to get
- 27:22Speaker 4: the answers. And then the one they love are the
- 27:26Speaker 4: ones they call the peacocks, which you just have to
- 27:28Speaker 4: kind of stroke their feathers, tell them they're pretty and smart,
- 27:32Speaker 4: and those are the ones they're going to sell your medication.
- 27:34Speaker 4: I mean they they know the psychology of doctors very well,
- 27:38Speaker 4: probably better than doctors do. So it is there's the
- 27:43Speaker 4: farm reps. It's changed maybe a little bit, but this
- 27:47Speaker 4: was this was like the most evil time of the
- 27:50Speaker 4: farm reps. Oh, they had the most power and doctors
- 27:53Speaker 4: were the least prepared to deal with. Right. Right.
- 27:55Speaker 3: It's also this kind of like there's less of an
- 27:57Speaker 3: inbuilt like immunity within the medical community because you guys
- 28:01Speaker 3: weren't used to being sold to this way. Yeah, it's
- 28:03Speaker 3: like when they first started getting Americans hooked on cigarettes,
- 28:06Speaker 3: and like people had never seen an advertisement before and
- 28:09Speaker 3: they're like a cowboy, well I'm buying a cigarette now,
- 28:15Speaker 3: So a later congressional inquiry found that Merk leadership divided
- 28:19Speaker 3: the studies on vyos into approved and background studies, and
- 28:23Speaker 3: any study that showed a danger to heart health was
- 28:25Speaker 3: considered a background study, and so their salespeople were forbidden
- 28:28Speaker 3: to discuss them with doctors. This was a violation of
- 28:31Speaker 3: company policy now all through two thousand and one. In
- 28:35Speaker 3: two thousand and two, the FDA sent letters to Merk
- 28:37Speaker 3: poking at it for failing to properly disclose the dangers
- 28:40Speaker 3: of viox, but it still took again fourteen months for
- 28:43Speaker 3: any sort of labeling change to be mandated. Part of
- 28:46Speaker 3: why is that officials within the FDA were in the
- 28:48Speaker 3: tank for Merk, not all of them, but enough. At
- 28:51Speaker 3: later Senate committee investigations, an FDA scientist testified that he
- 28:55Speaker 3: had brought forward concerns about viox to his superiors and
- 28:59Speaker 3: been pressured to shut up. Another researcher who had gone
- 29:02Speaker 3: to the FDA with complaints was Girk and Paul Singh,
- 29:05Speaker 3: a Stanford professor who claimed that a Merck senior executive
- 29:09Speaker 3: complained to his superiors at the university when he reported
- 29:12Speaker 3: yox to the FDA. Singh claimed I was warned that
- 29:15Speaker 3: if I persisted in this fashion, there would be serious
- 29:18Speaker 3: consequences for me, because, of course MRK has the ability
- 29:21Speaker 3: to donate a lot of money to a university like Stanford.
- 29:24Speaker 3: Now still, some brave academics continued to blow the whistle,
- 29:27Speaker 3: as this paragraph from a New York Times article by
- 29:30Speaker 3: Alex Berenson, Gardner, Harris, and Barry Meyers summarizes. In two
- 29:34Speaker 3: thousand and one, the first major study critical of the
- 29:36Speaker 3: drugs appeared in the Journal of the American Medical Association.
- 29:39Speaker 3: The report, written by Eric J. Tapol, and cardiologist at
- 29:42Speaker 3: the Cleveland Clinic, reanalyzed data from several clinical trials of
- 29:45Speaker 3: viox and celebrates. It reported that both drugs appeared to
- 29:48Speaker 3: increase the risk of heart attack and stroke, but that
- 29:51Speaker 3: the danger from biox appeared higher. Doctor Tapol, the chairman
- 29:55Speaker 3: of the Clinics Department of Cardiovascular Medicine, immediately called for
- 29:59Speaker 3: trials tol whether or not the drugs increased cardiovascular risk.
- 30:03Speaker 3: Merck and Pfizer both rebuffed that request and said that
- 30:06Speaker 3: the Cleveland Clinic report was flawed because it failed to do,
- 30:09Speaker 3: among other things, to include data from other studies. Doctor
- 30:13Speaker 3: Tipol became a harsh critic of both drugs, but his
- 30:15Speaker 3: ire focused on viox and MERK. Even before his two
- 30:18Speaker 3: thousand and one report repaired. He said in a recent
- 30:21Speaker 3: interview that company scientists came to Cleveland to try to
- 30:23Speaker 3: convince him not to publish it. Murk officials denied doing so.
- 30:28Speaker 3: A year later, a study by doctor Wayne Ray, an
- 30:30Speaker 3: epidemiologist at Vanderbilt University, found that medicaid patients in Tennessee
- 30:34Speaker 3: who were taking high doses of vyos greater than the
- 30:37Speaker 3: recommended long term dosage of twenty five milligrams daily had
- 30:40Speaker 3: significantly more heart attacks and strokes than similar patients who
- 30:43Speaker 3: were not taking high doses.
- 30:46Speaker 4: So back when Alex Berenson used to write useful.
- 30:49Speaker 3: Things, Yeah, it's okay, his careers move forward now he
- 30:56Speaker 3: doesn't have to do that anymore.
- 30:58Speaker 4: I don't know.
- 30:58Speaker 3: It's all pretty bad, right, Like that's I mean, there's
- 31:03Speaker 3: a degree to which like, at least you can see
- 31:05Speaker 3: these these heroes who tried to do something, even though
- 31:09Speaker 3: you know your university is telling you stop. MRK is
- 31:11Speaker 3: sending scary guys to your door to be like, are
- 31:14Speaker 3: you sure you want to publish that study?
- 31:16Speaker 2: You know?
- 31:16Speaker 4: Yeah, yeah it is it is funny, Like I didn't
- 31:20Speaker 4: realize until this how slow moving a car wreck. This
- 31:25Speaker 4: was yes, like this has been this a whole thing.
- 31:28Speaker 4: It's been happening for a while. It's I didn't realize
- 31:30Speaker 4: that it is someone. It's more nefarious than I expect it.
- 31:34Speaker 3: Yeah, well because MRK, Like, there's no argument they don't
- 31:37Speaker 3: know exactly what they're doing. They are trading lives for dollars.
- 31:40Speaker 3: The longer they know, eventually, we'll have to stop selling
- 31:43Speaker 3: this stuff because we know how dangerous it is. But
- 31:46Speaker 3: every day we get to keep selling it. We were
- 31:49Speaker 3: recouping that investment. We're making a profit, and whatever we
- 31:53Speaker 3: have to pay out in the end is going to
- 31:55Speaker 3: be less than what we're making.
- 31:57Speaker 4: I wonder how they justified it to themselves.
- 31:59Speaker 2: If they did money money money.
- 32:02Speaker 4: I know, and your listeners are like, what the fuck
- 32:04Speaker 4: is wrong with this guy? What kind of does he
- 32:06Speaker 4: not listen to the show? Does he not understand? But
- 32:08Speaker 4: I mean, like I feel like everybody.
- 32:10Speaker 2: Thinks like sheesh baby.
- 32:12Speaker 4: But like these farm like the people the head of
- 32:16Speaker 4: this farm company they are doing this now are how
- 32:20Speaker 4: like is are they lying to themselves in some way?
- 32:23Speaker 4: And what lie is that? That they're telling themselves. That's
- 32:25Speaker 4: the part I don't understand.
- 32:27Speaker 3: They know who to lie to and not they're lying
- 32:29Speaker 3: I think to a lot of the doctors and to
- 32:32Speaker 3: some of the salespeople. You know, salespeople don't maybe know
- 32:34Speaker 3: how to like analyze whether or not this is a
- 32:38Speaker 3: good study or whatever, so they're just like, oh, those
- 32:41Speaker 3: other studies that showed a danger, they're not good for
- 32:42Speaker 3: this reason or that reason. And like you're just some
- 32:45Speaker 3: fucking sales rep that got hired out of college. Maybe
- 32:47Speaker 3: you don't really give that much of a shit. But
- 32:49Speaker 3: there are people plenty of people who know exactly what
- 32:53Speaker 3: they're doing, right, And like those people who know exactly
- 32:57Speaker 3: what they're doing just don't care. They don't feel bad
- 33:00Speaker 3: about the fact that they're getting people killed.
- 33:02Speaker 4: Right. There's just like in every episode I do, there's
- 33:05Speaker 4: like this one moment where I turn to you and
- 33:07Speaker 4: I'm just like, Robert, why do bad people do bad things?
- 33:12Speaker 4: I just don't understand it. I'm so dumb in that way.
- 33:16Speaker 4: Yeah doesn't.
- 33:18Speaker 3: Yeah, I mean it's not dumb, you just aren't. You
- 33:21Speaker 3: just have a soul and.
- 33:23Speaker 4: I'm working to get rid of it.
- 33:25Speaker 3: Yeah, Well that's that's the only thing that's going to
- 33:27Speaker 3: let us win. We all have to get rid of
- 33:28Speaker 3: our souls today. Which, by the way, I've got a
- 33:31Speaker 3: great new medication for getting rid of your souls. First step,
- 33:34Speaker 3: you're going to go to your local not a local
- 33:36Speaker 3: gas station. Actually, you want to go to a truck
- 33:38Speaker 3: stop about thirty or forty minutes outside of town. Right
- 33:42Speaker 3: if you can actually like see like people like like.
- 33:47Speaker 3: If there's more than a half dozen rigs parked outside,
- 33:49Speaker 3: that's probably a good truck stop. And you're going to
- 33:51Speaker 3: go in there and behind the counter there should be
- 33:54Speaker 3: a wall of pills and you're just going to ask
- 33:56Speaker 3: for all of them, and you pour that into a cup.
- 33:58Speaker 3: And this is critical. You mix it in with mountain
- 34:02Speaker 3: dew code red, not Baja blast. That'll fuck it up.
- 34:05Speaker 3: Do not mix Baja blast in mountain dew code red.
- 34:10Speaker 3: And then shoot that ship as fast as possible. And
- 34:13Speaker 3: that's gonna get rid of your soul. And then you're
- 34:15Speaker 3: ready to join us on the front lines fighting the demons.
- 34:18Speaker 4: Don't don't do that, people.
- 34:19Speaker 3: You'll also be able to see demons. That's that's a promise.
- 34:24Speaker 2: Yeah, you're gonna see some demons.
- 34:29Speaker 6: Yeah, all of that fucking ibagain, or whether they fuck they
- 34:31Speaker 6: put us in those pills, those random trucker pills that
- 34:36Speaker 6: they just they all they almost call them adderall but
- 34:40Speaker 6: not quite.
- 34:42Speaker 4: I want to go check it out now. I mean,
- 34:44Speaker 4: I live in San Francisco, so we don't have like,
- 34:46Speaker 4: you know, forty minutes outside of town is like another town,
- 34:48Speaker 4: So I gotta like go pretty far.
- 34:50Speaker 3: You gotta go down the five to that place that
- 34:52Speaker 3: sells split piece soup. Uh and then yeah, yeah, yeah,
- 34:55Speaker 3: you can find there.
- 34:57Speaker 4: Yeah, all right, I'm gonna do it. Actually, I think
- 35:00Speaker 4: that's a good day trip.
- 35:00Speaker 3: Yeah, this will be good. Let's let's let's go do
- 35:02Speaker 3: it together. We'll buy all the Trucker pills and we'll
- 35:04Speaker 3: see how they.
- 35:05Speaker 4: Work to live stream that. I think that would really.
- 35:08Speaker 3: Oh yeah, oh yeah. So in late September two thousand
- 35:12Speaker 3: and four, as the death toll mounted and Merk's legal
- 35:15Speaker 3: team was buried in cases, they made the decision to
- 35:18Speaker 3: pull vax off the market all together. This is right
- 35:21Speaker 3: after the case has been decided against them. There is
- 35:23Speaker 3: no longer keeping this cat in the bag, and now
- 35:25Speaker 3: it's about damage control. Their official justification was that they
- 35:29Speaker 3: just had a long term clinical trial which showed that
- 35:31Speaker 3: some patients developed cardiovascular problems after taking the drug for
- 35:35Speaker 3: eighteen months. The data showed fifteen heart attack, strokes or
- 35:38Speaker 3: blood clots per thousand people over three years, compared with
- 35:41Speaker 3: seven and a half cardiac events in the general population.
- 35:44Speaker 3: And even if you believe this Merk study, which I
- 35:47Speaker 3: think is kind of trying to pad how bad it is,
- 35:51Speaker 3: that's still much worse's that's still.
- 35:53Speaker 2: A real problem.
- 35:55Speaker 3: The stock market reacted first, costing Merk somewhere in the
- 35:58Speaker 3: neighborhood of twenty six billion dollars in a day. But
- 36:00Speaker 3: that's not real money. They get it back, you know
- 36:02Speaker 3: how the stock market works. The next reaction came from
- 36:05Speaker 3: the families of people who died due to viox, leading
- 36:07Speaker 3: to a rush of new lawsuits. But the initial public
- 36:10Speaker 3: reaction was beyond muted. It was, in fact, downright hostile
- 36:14Speaker 3: to the victims. And this likely has something to do
- 36:17Speaker 3: with a particularly toxic aspect of US culture I call
- 36:20Speaker 3: scalding McDonald's coffee syndrome. Now, you probably heard the story
- 36:24Speaker 3: about the woman who had a hot coffee spill in
- 36:26Speaker 3: her lap at McDonald's drive through, and she sued them
- 36:29Speaker 3: and got a bunch of money. This is a thing
- 36:31Speaker 3: that especially when I was younger. I think more people
- 36:33Speaker 3: know their real story now, But you would see viral
- 36:35Speaker 3: memes all the time. You'd see it in like newspapers.
- 36:38Speaker 3: You know, it was really a thing like my parents'
- 36:40Speaker 3: generation loved to hate on. It was particularly a big
- 36:43Speaker 3: thing for like conservatives who were angry at how mean
- 36:46Speaker 3: all these slight, these frivolous lawsuits hurting innocent corporations, Like
- 36:50Speaker 3: this woman spills coffee in her own lap, and like
- 36:52Speaker 3: the reality was McDonald's had the coffee way higher than
- 36:55Speaker 3: they were legally allowed to have it. They should not
- 36:57Speaker 3: have been selling or handing people coffee hot and it
- 37:01Speaker 3: gave her third degree burns to like her entire genital area.
- 37:04Speaker 3: Like it was a hideous, hideous, life altering injury that
- 37:08Speaker 3: she suffered because they were not doing what they legally
- 37:10Speaker 3: should have been doing. Anyway, we don't need to rant
- 37:12Speaker 3: on this, but at the time this happens, a lot
- 37:15Speaker 3: less people realize the true story there, and so there
- 37:18Speaker 3: is this big backlash against frivolous lawsuits against companies and
- 37:23Speaker 3: what the murk vax lawsuits initially get lost in that right.
- 37:28Speaker 3: When Carol von Ernst won her case against Merk, A
- 37:31Speaker 3: lot of pundits of the day kind of looped this
- 37:32Speaker 3: in with the McDonald's coffee case as another example of
- 37:35Speaker 3: our sue happy culture run amok. From the book Poison Pills,
- 37:39Speaker 3: Carol Earnst. Lawyer Mark Lanier was blasted by everyone from
- 37:42Speaker 3: physicians to newspaper columnists for winning the trial by twisting
- 37:45Speaker 3: the facts and relying on nothing but an ignorant jury
- 37:48Speaker 3: of hicks, despite the fact that his witnesses included some
- 37:51Speaker 3: of the best known physicians and scientists in the world.
- 37:54Speaker 3: Even as the Texas jury was deliberating, Merk's lead attorney,
- 37:57Speaker 3: Jerry Lowry, said if he Lanier had any evidence causes arrhythmia,
- 38:01Speaker 3: this case would have been over three weeks ago. A
- 38:03Speaker 3: few months after the trial verdict, CNBC broadcast a debate
- 38:07Speaker 3: between Lanier and Richard Epstein, the James Parker Hall Distinguished
- 38:10Speaker 3: Service Professor of Law at the University of Chicago and
- 38:12Speaker 3: a senior fellow at the Hoover Institute. The professor had
- 38:15Speaker 3: written an op ed piece for The Wall Street Journal
- 38:17Speaker 3: and said that physicians lamented the fact that they could
- 38:19Speaker 3: no longer use the drug. Many leading newspapers, including The
- 38:22Speaker 3: Washington Post, also mocked the Ernst trial. In an editorial
- 38:26Speaker 3: entitled the viox Hex, the Post wrote that the Texas
- 38:29Speaker 3: jury in that case awarded two hundred and fifty three
- 38:31Speaker 3: point four million to the widow of a man who
- 38:33Speaker 3: died of a heart attack triggered by arrhythmia, which is
- 38:35Speaker 3: not a conditioned Viyax has been proven to cause. The
- 38:38Speaker 3: Post said, the jury was confused about the medical evidence.
- 38:41Speaker 3: And this is number one, that fucking dude debating Laneer
- 38:44Speaker 3: on stage as a Hoover Institute guides right wing thing tape.
- 38:47Speaker 3: But number two, you've got all these like big publications
- 38:49Speaker 3: going like, oh, these it's a Texas jury. So clearly
- 38:52Speaker 3: they're hicks. They don't understand our big cities science. They
- 38:56Speaker 3: just got bamboozled by this smooth talking law who just
- 39:00Speaker 3: hated Merk.
- 39:02Speaker 2: It's so fucked up.
- 39:04Speaker 4: You're totally right. It was like this era where it
- 39:06Speaker 4: was like people like there has to be personal accountability
- 39:09Speaker 4: for this, Like they should have known that there was
- 39:12Speaker 4: a small risk with medications, and they, I mean, they're
- 39:15Speaker 4: missing the point, which was that the risk was obfuscated
- 39:20Speaker 4: in the beginning, I think, I mean, it sounds like,
- 39:22Speaker 4: to be honest with you, it it's still at some
- 39:26Speaker 4: point they look back at these medications and they said,
- 39:30Speaker 4: you know what, there might be a role for them,
- 39:32Speaker 4: and they're actually, you know, very well, could be a
- 39:35Speaker 4: good use for some of these uses and stuff, right,
- 39:39Speaker 4: I mean, even viox could have had specific uses for
- 39:43Speaker 4: very well chosen patients. And they'll never get to that.
- 39:48Speaker 4: Those patients will never get to that. They'll never get
- 39:50Speaker 4: to have that benefit of a medicine that could actually work.
- 39:53Speaker 4: Because again, instead of all the money going into research
- 39:56Speaker 4: development figuring out exactly who benefits and who gets harmed
- 40:00Speaker 4: from it and who should have it and who shouldn't,
- 40:02Speaker 4: they spent all their money and energy in finding ways
- 40:05Speaker 4: to sell it and for as long as possible, and
- 40:08Speaker 4: they painted themselves into a corner at the end, and
- 40:11Speaker 4: they couldn't at that point and then say, okay, well,
- 40:14Speaker 4: actually the only these small set of people should use
- 40:18Speaker 4: the medication because the risk is then worth it in
- 40:21Speaker 4: these the small subset. But they couldn't do that. They
- 40:23Speaker 4: had to withdraw completely. So it's just so stupid on
- 40:27Speaker 4: so many levels. It's so it's such a waste, and
- 40:31Speaker 4: it's a waste of all the time and effort that
- 40:33Speaker 4: went into making the medication. Again too, because again the
- 40:36Speaker 4: concept behind the medication, looking at COX two inhibitors, looking
- 40:40Speaker 4: at ways to selectively attack those pain the pain pathways,
- 40:44Speaker 4: shut down the pain pathways before they cascade into inflammation
- 40:48Speaker 4: and pain. It's all smart, it's good. And now now
- 40:51Speaker 4: it's my knowledge, I don't know if people are even
- 40:53Speaker 4: thinking about this anymore. And like we still have problems
- 40:56Speaker 4: with ensades end says still cause problems. Lots of health
- 40:59Speaker 4: problems still come from advil leve I profen. They still
- 41:02Speaker 4: cause me headaches because I have to go and take
- 41:04Speaker 4: care of people believing because of them that cause hard issues,
- 41:06Speaker 4: kidney problems, liver problems. Like people should be we should
- 41:10Speaker 4: be researching new paid medications and worrying about how to
- 41:15Speaker 4: do that right as opposed to how to make as
- 41:17Speaker 4: much money off of as possible. But that's not where
- 41:19Speaker 4: we are, it's not who we are. So I don't
- 41:21Speaker 4: know why I'm saying this.
- 41:22Speaker 3: I'm just no, I mean, it's it's all very frustrating, right,
- 41:25Speaker 3: Like the way that this worked is just comprehensively bad
- 41:29Speaker 3: for everybody but a handful of people at the top
- 41:32Speaker 3: of mark. It's bad for the research scientists at MERK
- 41:36Speaker 3: who were not shady motherfuckers who will always exist under
- 41:39Speaker 3: a cloud of suspicion because they worked during the vox era.
- 41:43Speaker 3: It's bad for the people who might have benefited from
- 41:45Speaker 3: a VIAX that was rolled out in a more reasonable
- 41:47Speaker 3: way to a smaller subset of people. It's bad for
- 41:50Speaker 3: all of the tens of thousands of people who lost
- 41:53Speaker 3: loved ones and the people who had life altering injuries
- 41:55Speaker 3: as a result of it. It's just terrible for everybody.
- 41:58Speaker 3: But you know, doctor Hoode, not terrible for anybody. What's
- 42:02Speaker 3: that products and services that support this podcast, all of
- 42:05Speaker 3: which have been FDA approved, And if we've learned anything
- 42:08Speaker 3: this episode, that always means good, good, and we're back.
- 42:18Speaker 3: So we're drawing to a close in this episode.
- 42:23Speaker 4: I have a question. Did they actually lose money overall
- 42:27Speaker 4: from this? How much? Do we know? How much?
- 42:30Speaker 6: No?
- 42:30Speaker 3: No, no, no. They pay in total a little less
- 42:33Speaker 3: than a billion dollars in penalties and additional civil settlements
- 42:36Speaker 3: for their victim. They are making two and a half
- 42:37Speaker 3: billion dollars a year during the period of time where
- 42:40Speaker 3: they're selling this and it's been it's out for five years,
- 42:43Speaker 3: something like five years. Yeah yeah, okay, yeah, so that's cool.
- 42:49Speaker 4: Now.
- 42:49Speaker 3: One of my favorite side parts in this story is
- 42:51Speaker 3: that the Washington Posts takes like a huge strong stance
- 42:55Speaker 3: to defend an unethical mega corporation and got something wrong,
- 42:59Speaker 3: which is not a thing that iver happens again.
- 43:02Speaker 2: Anyway.
- 43:04Speaker 3: About a year after the Post's article talking about how
- 43:07Speaker 3: unfair it is to Suemer, Harvard's School of Public Health
- 43:10Speaker 3: issues a public health bulletin warning that vyax use was
- 43:13Speaker 3: associated with severe heart rhythm disorders and an increased risk
- 43:17Speaker 3: of kidney failure. More research comes out in the following
- 43:19Speaker 3: years that further vindicates everyone who tried to Warren Mrk
- 43:22Speaker 3: and the world about biox the medication that had been
- 43:25Speaker 3: prescribed to some twenty million people in eighty countries by
- 43:28Speaker 3: the time it was polled. We will never have a
- 43:30Speaker 3: comprehensive list of the number of people killed and injured
- 43:32Speaker 3: as a result of viox, but what we do know
- 43:34Speaker 3: is harrowing. Doctor David Graham, the Associate Director for Science
- 43:38Speaker 3: and Medicine and the FDA's Office of Drug Safety, testified
- 43:41Speaker 3: before the Senate Finance Committee that Yax had been associated
- 43:44Speaker 3: with at least one hundred thousand heart attacks and more
- 43:47Speaker 3: than fifty five thousand premature deaths, that is, in the
- 43:50Speaker 3: United States. He compared the cost to two to four
- 43:54Speaker 3: jumbo jetliners crashing every week for five years.
- 43:58Speaker 4: Well it shit, yeah, striking imagery.
- 44:03Speaker 2: Yes, that's a lot of dead people.
- 44:06Speaker 4: God.
- 44:08Speaker 3: Now, the lawsuits that resulted from this are far too
- 44:10Speaker 3: numerous to chronicles, save to note that Merk initially promised
- 44:13Speaker 3: to fight each of the thirty thousand lawsuits against them independently.
- 44:17Speaker 2: Well, fight everyone, yes, man.
- 44:21Speaker 3: Then they agreed in two thousand and eight to provide
- 44:23Speaker 3: what could have been almost five billion as part of
- 44:26Speaker 3: the settlement, but I don't know how much of that
- 44:28Speaker 3: they actually paid out. And then they pled guilty to
- 44:32Speaker 3: a misdemeanor for a legal promotional activity that was about
- 44:36Speaker 3: another nine hundred and fifty million in penalties and civil payments.
- 44:39Speaker 3: So you know, they wound up paying a good amount
- 44:42Speaker 3: of money. That's like they lost a good like two
- 44:43Speaker 3: years or so of the profits that they made.
- 44:47Speaker 4: Did Dorothy Hamil do anytime? No?
- 44:49Speaker 3: No, Dorothy Hamill does not go to prison for him.
- 44:51Speaker 3: Many many crimes. They do plead guilty to a misdemeanor
- 44:56Speaker 3: for introducing a misbranded drug to interstate commerce, So that's nice.
- 45:00Speaker 3: But no one at Merk is locked up for what
- 45:02Speaker 3: they did. Nor do any of the scientists who degree
- 45:04Speaker 3: to help cover up studies or push this info suffer
- 45:06Speaker 3: lasting career harms, with the notable exception of our friend
- 45:10Speaker 3: Scott Ruben. Paul White, the editor at the Journal of
- 45:13Speaker 3: Anesthesia and Analgesia, claims that Ruben's study showing the benefits
- 45:17Speaker 3: of COX two inhibitors helped sell billions of dollars worth
- 45:20Speaker 3: of both celebres and vox. In two thousand and nine,
- 45:23Speaker 3: he was revealed to have completely falsified at least twenty
- 45:25Speaker 3: one of his published papers, all of which claimed to
- 45:28Speaker 3: show how else super aspirins could benefit post operative healing.
- 45:31Speaker 3: Pfiser had funded Ruben's work from two thousand and two
- 45:33Speaker 3: to two thousand and seven, the years when they were
- 45:35Speaker 3: also making bank on a little medication called Celebrex. His employer,
- 45:39Speaker 3: Bay State Medical Center, claimed a Scientific American that Ruben
- 45:42Speaker 3: had been paid directly by Pfeiser for his work, and
- 45:46Speaker 3: that he had been decided how much of that money
- 45:48Speaker 3: would fund research and how much would go into his pocket,
- 45:51Speaker 3: which sounds fine, that's not sketchy, there's nothing. How could
- 45:57Speaker 3: that lead to anything?
- 45:58Speaker 2: Bad man?
- 46:00Speaker 4: You know, it's giving antithesiologists a bad name.
- 46:03Speaker 2: It is, it is, and.
- 46:04Speaker 4: These are guys who deal with a lot of fentanyl.
- 46:06Speaker 4: So that is wild. That is well. I am actually
- 46:12Speaker 4: I would love to read his articles that are totally fabricating.
- 46:17Speaker 3: Oh yeah, there's some good breakdowns on them from scientists
- 46:21Speaker 3: who are more qualified than me to talk about it.
- 46:24Speaker 4: I do recommend.
- 46:24Speaker 3: It's a fascinating story. One of my favorite quotes from
- 46:28Speaker 3: this is that his employer, Base Date, like when people
- 46:31Speaker 3: would note that, like, well, that's not how pharmaceutical You're
- 46:33Speaker 3: not just supposed to give a single guy cash, Like
- 46:37Speaker 3: that's not how pharmaceutical research is supposed to be done.
- 46:40Speaker 3: A spokesman for Base State Medical Center told Scientific American,
- 46:43Speaker 3: I don't know how many dollars went to Ruben or
- 46:45Speaker 3: his group.
- 46:47Speaker 2: Wow, no idea, Holy hell.
- 46:51Speaker 3: A Pfiser spokesperson insisted the grants we're properly dispersed to
- 46:56Speaker 3: Base State in accordance with Pfiser policy, but that they
- 46:59Speaker 3: weren't familiar with the record's retention policies of base state,
- 47:03Speaker 3: so you know, who knows, who knows how much money
- 47:07Speaker 3: between ten and one hundred thousand dollars at least, But
- 47:10Speaker 3: he was actually asked to pay three hundred and sixty
- 47:12Speaker 3: thousand dollars in restitution when he got sentenced in twenty
- 47:16Speaker 3: ten after pleading guilty of massive fraud. Prosecutors argued that
- 47:20Speaker 3: he'd been paid huge money in grants and never performed
- 47:23Speaker 3: the studies he'd been paid to conduct. He just pocketed
- 47:26Speaker 3: the cash and published lies about celebres. Thankfully, justice was done.
- 47:30Speaker 3: He was given six months in prison and asked to
- 47:33Speaker 3: pay three hundred and sixty thousand in restitution to the
- 47:36Speaker 3: pharmaceutical companies who'd sponsored his work, the real victims and
- 47:39Speaker 3: all this holy shit.
- 47:41Speaker 4: Yeah, actually, I mean he did some time. That's something.
- 47:44Speaker 4: I mean, I do know doctors that's gone to actual
- 47:47Speaker 4: prison for like medicare fraud and that sort of thing,
- 47:49Speaker 4: like done actual time. It's not common, but you know,
- 47:55Speaker 4: it can certainly happen. I mean, the things I'm seeing
- 47:58Speaker 4: are there, it's always fraud related, you know. And actually
- 48:02Speaker 4: six months isn't as long as I've seen other people
- 48:05Speaker 4: go for what I kind of consider to be lesser crimes,
- 48:08Speaker 4: but they weren't crimes committed directly against the American government
- 48:12Speaker 4: and medicare frauds, So that's probably why he only got
- 48:15Speaker 4: six months.
- 48:16Speaker 2: Yep.
- 48:18Speaker 3: Yeah, and that's the story of biocs. Doctor Hoode. How
- 48:22Speaker 3: are you feeling?
- 48:22Speaker 2: How are you good?
- 48:23Speaker 4: I mean, you know, I again, it comes down to
- 48:27Speaker 4: like I'm always a little torn when I do episodes
- 48:30Speaker 4: or talk about how terrible pharmaceutical companies are, because they
- 48:33Speaker 4: are terrible and I have so many problems with them,
- 48:37Speaker 4: but there's always a part of me that's like they
- 48:41Speaker 4: are super important at the same time, and we do
- 48:44Speaker 4: need them more than ever to be really focused on
- 48:47Speaker 4: important world health issues and infectious diseases. And the problem
- 48:55Speaker 4: is the things I really care about, the things I
- 48:58Speaker 4: think are really important, are not necessarily things that they're
- 49:00Speaker 4: going to make money off of, and they just don't
- 49:03Speaker 4: really care. So I'm very torn. I have a lot
- 49:05Speaker 4: of mixed emotions about pharmaceutical companies in general, and it
- 49:09Speaker 4: bothers me when people assume that I am like pro
- 49:14Speaker 4: pharmacutical company because I hate them more than anybody really,
- 49:18Speaker 4: I mean, I really do. But at the same time,
- 49:21Speaker 4: we do need their help unless we get more scientists
- 49:25Speaker 4: like doctor Peter Hotez, who's you know, a friend of
- 49:29Speaker 4: the show has come on who has made his own
- 49:32Speaker 4: pharmacutic or like vaccines at cost, these great like vaccines,
- 49:37Speaker 4: and people still accuse him of being a pharmacial even
- 49:40Speaker 4: though he works completely outside of the farmer world. So
- 49:43Speaker 4: I'm very torn about pharmacual companies in general, and I
- 49:48Speaker 4: think it is very very very important that we continue
- 49:52Speaker 4: to like pick at them, analyze them, be super critical
- 49:56Speaker 4: of them, but also be fair about what they can
- 50:00Speaker 4: can do, what they should do, and what we should
- 50:03Speaker 4: expect from them. I think we have to be able
- 50:05Speaker 4: to look at them critically and look at them in
- 50:07Speaker 4: a sort of we have to look at them critically,
- 50:10Speaker 4: but we also have to be able to be fair
- 50:13Speaker 4: and reasonable about what we expect from a massive corporation.
- 50:17Speaker 4: These are examples, like this case here of things that
- 50:21Speaker 4: should never have been allowed to have happened and are
- 50:25Speaker 4: going to continue to happen because we aren't going to
- 50:29Speaker 4: have the oversight of these companies and it's going to
- 50:31Speaker 4: become easier and easier for things like this to happen,
- 50:34Speaker 4: which is my fear unless doctors and scientists around the
- 50:39Speaker 4: world have the time and energy to really pick apart
- 50:43Speaker 4: at every detail and every study that comes from them.
- 50:47Speaker 4: But I think even academic medicine is going to be
- 50:50Speaker 4: under the gun in the coming years too. I don't
- 50:53Speaker 4: feel great for my friends who have, like who have
- 50:57Speaker 4: academic jobs in medicine. I think they're all going to
- 50:59Speaker 4: be at who's going to get paid, who's going to
- 51:01Speaker 4: be able to get to stay, who's going to be
- 51:03Speaker 4: able to get their research done. It's all going to
- 51:05Speaker 4: be at the whim of people who know very little
- 51:08Speaker 4: about science, who care very little about science. So very
- 51:12Speaker 4: depressed is the answer to your question.
- 51:15Speaker 3: Yeah, I mean that's yeah. There's not much more to
- 51:18Speaker 3: say on the matter than that, right, Like this is
- 51:21Speaker 3: I guess part of what's so frustrated to me is
- 51:23Speaker 3: that the sweep of like the anti intellectual crusade that
- 51:27Speaker 3: is going to cost so many people their lives, is
- 51:30Speaker 3: of such catastrophic danger to every positive gain that we've
- 51:35Speaker 3: made as a society in the last one hundred and
- 51:37Speaker 3: fifty years. Is fueled in part by the irresponsibility, greed,
- 51:43Speaker 3: and wastefulness of people who knew better who are not ideologues,
- 51:47Speaker 3: who are not misinformed, who are just willing to well,
- 51:53Speaker 3: the system can handle, you know, me fucking around in
- 51:56Speaker 3: this way, or like why shouldn't I get paid?
- 51:58Speaker 4: Right?
- 51:58Speaker 3: Like, someone will catch it, it won't be that bad. Like,
- 52:01Speaker 3: And those little acts of malfeasance provide a lot of
- 52:04Speaker 3: the fuel, like the distrust, the hatred for elites and whatnot.
- 52:10Speaker 3: You know, when I say elites, I mean like in
- 52:12Speaker 3: you know, the medical sense, right, You've got doctors and
- 52:15Speaker 3: people at the FDA who are like in the tank
- 52:17Speaker 3: for these sketchy drugs that get people killed. And that
- 52:20Speaker 3: means that when we have a fucking pandemic, less people
- 52:23Speaker 3: trust them. Right, Like vax is not zero percent of
- 52:27Speaker 3: why so many people were hesitant to trust medical science
- 52:31Speaker 3: during COVID, right, and neither is the opiate epidemic. Right,
- 52:34Speaker 3: And that that doesn't mean that the people that RFK
- 52:36Speaker 3: has a point. It means that, like, if you let
- 52:40Speaker 3: people get away with shit like this, and we always do, uh,
- 52:45Speaker 3: it'll just keep getting worse. Somebody who is who is
- 52:48Speaker 3: absolutely has no limits whatsoever, will start taking advantage of
- 52:51Speaker 3: the situation.
- 52:53Speaker 4: Yeah, that's exactly right.
- 52:54Speaker 2: Yea, that's exactly right.
- 52:56Speaker 4: So, yeah, it's going to be a wild four years.
- 52:59Speaker 4: There be so much diarrhea.
- 53:02Speaker 2: Yeah, there's gonna be a lot of diarrhea.
- 53:03Speaker 3: Look, folks, every year I go to Vegas, I find
- 53:06Speaker 3: whichever buffet has the rancidest muscles, and I eat fourteen
- 53:10Speaker 3: to fifteen plates, and that provides me with the internal
- 53:15Speaker 3: strength and resilience I need to handle any kind of
- 53:19Speaker 3: change to our health and safety food standards. I'm going
- 53:21Speaker 3: to be fine in this this sick new world, Kava.
- 53:24Speaker 3: I'm going to be eating rancid muscles like a king.
- 53:27Speaker 4: So many, so many food born illnesses, so much. It's
- 53:33Speaker 4: gonna be the.
- 53:34Speaker 3: It's gonna be the Golden Age of diarrhea, the brown Age.
- 53:37Speaker 2: Really, yeah, that's what. That's what I'm gonna call this, the.
- 53:40Speaker 3: The Guilden Age and the uh the brown Age. Well,
- 53:44Speaker 3: actually we could call it the guilt and age, which
- 53:45Speaker 3: is an old timey term for like shit encrusted on
- 53:49Speaker 3: your your ass. Perfect well, explain it, but it works. Yeah,
- 53:52Speaker 3: you have to explain it. You have to explain it.
- 53:54Speaker 3: But you know, why does that make it bad?
- 53:57Speaker 2: Anyway?
- 53:57Speaker 1: No?
- 53:58Speaker 2: Yeah, all right?
- 54:00Speaker 4: For having meat, Yeah, it's always good it's nice seeing you,
- 54:03Speaker 4: nice in your face. For your listeners who may have
- 54:07Speaker 4: an interest in learning more about medical topics, you can
- 54:11Speaker 4: listen to my podcast The House of Pod anywhere you
- 54:13Speaker 4: get your podcasts, and uh follow me applu skuy at
- 54:17Speaker 4: cave MT and thank.
- 54:21Speaker 3: You yeah, thanks for coming on the sheer.
- 54:29Speaker 1: Behind the Bastards is a production of cool Zone Media.
- 54:32Speaker 1: For more from cool Zone Media, visit our website cool
- 54:35Speaker 1: Zonemedia dot com or check us out on the iHeartRadio app,
- 54:39Speaker 1: Apple Podcasts, or wherever you get your podcasts. Behind the
- 54:42Speaker 1: Bastards is now available on YouTube, new episodes every Wednesday
- 54:46Speaker 1: and Friday. Subscribe to our channel YouTube dot com slash
- 54:50Speaker 1: at Behind the Bastards